Nutritional supplements that contain curcumin -- a natural anti-inflammatory compound -- may protect the eyes from the ...

CHICAGO -- Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a ...

Age-related macular degeneration (AMD) is one of the leading causes of vision ... Since AMD is closely linked with aging, some researchers have turned their attention to metformin—a drug better known ...

Age-related macular degeneration (AMD) is one of the leading causes of vision ... Since AMD is closely linked with aging, some researchers have turned their attention to metformin—a drug better known ...

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

Roche has released positive topline one-year findings from a Phase IV trial of Vabysmo (faricimab) to treat diabetic macular ...

Age-related macular degeneration (AMD ... "This kind of pharmaco-epidemiological study is relatively new in France," said Florian Sennlaub, research director at Vision Institute in Paris, France ...

This growth in the Age-Related Macular Degeneration market is fueled by ... in research and development investments that lead to more drug approvals and improved reimbursement policies.

Age-related macular degeneration (AMD ... some researchers have turned their attention to metformin—a drug better known for treating type 2 diabetes—because of promising data on its overall ...

The global AMD drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion by 2029, reflecting a robust ...